MRSA is resistant to:
The core concept here is beta-lactam antibiotics and resistance mechanisms. MRSA specifically has a gene called mecA that codes for an altered penicillin-binding protein (PBP2a), which has low affinity for beta-lactam antibiotics. This makes them resistant to methicillin and other beta-lactams like oxacillin, cephalosporins, and carbapenems. But they might still be susceptible to non-beta-lactam antibiotics such as vancomycin, linezolid, or daptomycin.
Now, looking at the answer options, even though they are not listed, the correct answer should be a beta-lactam antibiotic. Common distractors might include other classes like aminoglycosides or macrolides, which MRSA isn't resistant to. For example, if an option is ampicillin, that's a beta-lactam, so MRSA would be resistant. Another option might be vancomycin, which is correct for susceptibility. I need to explain why each wrong option is incorrect based on their class and resistance mechanisms.
The clinical pearl here is that MRSA is resistant to all beta-lactam antibiotics except maybe some specific ones like ceftaroline. Students should remember that the mecA gene is responsible for this resistance. Also, the term "methicillin-resistant" directly points to resistance against methicillin and related beta-lactams.
**Core Concept**
MRSA (Methicillin-Resistant *Staphylococcus aureus*) demonstrates resistance to beta-lactam antibiotics due to the *mecA* gene, which encodes an altered penicillin-binding protein (PBP2a). This protein has low affinity for beta-lactams, preventing cell wall inhibition.
**Why the Correct Answer is Right**
MRSA is resistant to all beta-lactam antibiotics, including methicillin, oxacillin, cephalosporins, and carbapenems. The *mecA*-mediated PBP2a bypasses the need for functional PBPs targeted by these drugs, rendering them ineffective. This resistance is distinct from beta-lactamase production, which degrades antibiotics but is not the primary mechanism in MRSA.
**Why Each Wrong Option is Incorrect**
**Option A:** *Vancomycin*—MRSA is **susceptible** to glycopeptides like vancomycin unless it acquires additional resistance (e.g., VISA/VRE).
**Option B:** *Clindamycin*—Resistance to lincosamides is acquired via ribosomal target modification, not the *mecA* gene.
**Option C:** *Rifampin*—Resistance to rifamycin requires mutations in RNA polymerase genes; MRSA is inherently susceptible.
**Option D:** *Linezolid*—Oxazolidinones inhibit protein synthesis and are effective against